News

The combination of amlodipine and olmesartan was demonstrated to be superior to monotherapy with either agent in difficult-to-treat hypertensive populations in a subgroup analysis of the registrational trial for this combination therapy. These results were presented at the 23rd Annual Scientific Meeting of the American Society of Hypertension, New Orleans, May 14–17, 2008.

The number of major employers offering employee wellness programs with incentives grew over the past year, according to a study presented by Health2 Resources. The National Association of Manufacturers and The ERISA Industry Committee participated in the survey.

The National Committee for Quality Assurance’s (NCQA’s) proposed standards and measures for a new Wellness and Health Promotion (WHP) product evaluation have been released for public comment.

Access to coverage, especially for individuals and small groups, is a constant issue. So much so that many Americans are taking great steps to change their lifestyles in order to obtain it. Get married to gain access to insurance? Some are doing just that.

U.S. drug regulators are said to be close to allowing doctors to e-prescribe addictive medications, including painkillers. According to Reuters, the Drug Enforcement Administration is expected to publish a proposal on e-prescribing controlled substances.

Two votes from Republican senators killed a House bill that would have averted statutory payment reductions for Medicare physicians, just before legislators left Capitol Hill for their Independence Day holiday. Medicare physicians now face 10.6% fee cuts, but there is an opportunity for retrospective increases after the recess.

Real-time continuous glucose monitoring (CGM) can significantly improve glycemic control, but it will not help all patients. "Real-time CGM will add significantly to glucose management for some people, but not for all," said Irl Hirsch, MD, University of Washington, Seattle. "Human factors make all the difference between success and failure. Some patients will never figure it out. That?s why real-time control is so challenging.

Good glycemic control is not sufficient to relieve painful diabetic neuropathy, necessitating investigation of other modalities to achieve analgesic efficacy. Dan Ziegler, MD, German Diabetes Clinic, German Diabetes Center, and professor of internal medicine, Leibniz Institute at the Heinrich Heine University, Düsseldorf, provided an overview of pharmacologic treatments that have been explored for painful diabetic neuropathy and the success achieved with each.

Clinicians and type 2 diabetes patients have a new worry: hepatic steatosis, or nonalcoholic fatty liver disease. Liver disease is a less-obvious problem than kidney disease but may have equally grave consequences.

Healthcare reform is a high-profile issue in the presidential election campaign, and drug access has become a central theme in the debate. Both Democratic and Republican candidates have rolled out healthcare reform plans that promise to cover the uninsured while also providing tax breaks and other incentives to help individuals obtain health insurance.

Ambulatory patients with cancer who are undergoing chemotherapy should not receive prophylactic anticoagulation to prevent venous thromboembolism, according to new guidelines developed by ASCO. "It's not cost effective and we also do not recommend screening these patients for thrombophilia," said Mark Levine, MD, McMaster University, Hamilton, Ontario, Canada.

Physicians treating cancer-related depression with paroxetine should not expect patients' insomnia to also improve, according to a study presented by Oxana G. Palesh, PhD, University of Rochester Cancer Center, NY. "We know that insomnia and depression often occur together frequently in the general population, suggesting that there may be a common mechanism," she said.

Metformin may represent a novel antitumor agent, say investigators from the University of Texas M.D. Anderson Cancer Center, Houston.

Advanced age should not be a barrier to initiating adjuvant chemotherapy in patients with stage III colon cancer. In an observational study, the oldest patients suffered no more adverse events when treated with adjuvant chemotherapy than did younger patients but were much less likely than their younger counterparts to actually receive adjuvant chemotherapy for their colon cancer, said Katherine L. Khan, MD, professor of medicine at the University of California, Los Angeles.

Cancer-related fatigue significantly interferes with patients' quality of life, and some areas often affected among these patients are not normally included on standard quality-of-life assessments, said Karen M. Mustian, PhD, University of Rochester School of Medicine, NY. More randomized, controlled trials are needed to identify these areas, she said.

An RNA signature present in blood that is highly accurate for detecting prevalent lung cancer can accurately predict the development of lung cancer within the next 2 years 80% of the time, said Thomas Zander, MD, Department of Internal Medicine and the Center for Integrated Oncology, University Clinic Cologne, Germany. "Early detection of lung cancer is a major need, as most patients present for diagnosis at a late stage when there is no chance for cure," Dr Zander said. Two-year survival after a lung cancer diagnosis is approximately 15%. Early detection may therefore be a promising strategy to improve survival rates.

Most elderly patients do not receive combined modality treatment (CMT) with both chemotherapy and radiation for locally advanced, non-small cell lung cancer (NSCLC) despite trial data indicating that CMT enhances survival, decreases comorbidities, and is potentially curative. Data presented by Martin J. Edelman, MD, professor of medicine, University of Maryland Greenebaum Cancer Center, Baltimore, indicate that elderly patients receiving chemotherapy followed by concurrent chemotherapy and radiation derive the most significant survival benefit.

Strict evidence-based criteria should be used when prescribing erythropoiesis-stimulating agents (ESAs) for cancer, as ESAs appear to activate signaling pathways that are important in altering tumor behavior and treatment response, experts said.

The extent to which patients should have access to experimental therapies is a hotly contested issue, and courts and regulatory agencies have wrestled with the problems involved when an individual is willing to be treated with unapproved drugs at the potential expense of causing harm not only to the individual but to the clinical trial process itself.

Patients with metastatic colorectal cancer are more likely to respond to initial treatment that includes cetuximab if they have nonmutated, wild-type KRAS gene status, reported Eric Van Cutsem, MD, University Hospital Gasthuisberg, Leuven, Belgium. "For the first time in colorectal cancer, we are able to predict which patients are likely to be helped by the new biologics," he said. "KRAS is the first molecular marker for the selection of a targeted therapy in combination with a standard chemotherapy regimen in first-line metastatic colorectal cancer. KRAS testing should be routinely conducted in all colorectal cancer patients immediately after diagnosis to ensure the best treatment strategies for the individual patient."

An investigational 500-mcg dose of interferon beta-1b demonstrated no advantage compared with the approved 250-mcg dose of interferon beta-1b or with glatiramer 20 mg in reducing relapse risk in patients with early relapsing-remitting multiple sclerosis (RRMS), said Paul O'Connor, MD, MS Program Director, St. Michael's Hospital, the University of Toronto, at the 60th Annual Meeting of the American Academy of Neurology, Chicago.

Lacosamide safely decreases pain scores in patients with painful diabetic neuropathy, according to a pooled efficacy and safety analysis presented at the 60th Annual Meeting of the American Academy of Neurology, Chicago.